Grufity logoGrufity logo

INO

1.83USD+0.04(+2.23%)Market Closed

Inovio Pharmaceuticals Inc

Market Summary

USD1.83+0.04Market Closed
2.23%

INO Stock Price

RSI Chart

Valuation

Market Cap

551.2M

Price/Earnings

-1.55

Price/Sales

343.43

Price/Cashflow

-2.8

MarketCap/EBT

-1.56

Price/Sales

Profitability

EBT Margin

-21965.49%

Return on Equity

-119.17%

Return on Assets

-77.21%

Fundamentals

Revenue

Revenue (TTM)

2.2M

Revenue Y/Y

78.23%

Revenue Q/Q

59.24%

Earnings

Earnings (TTM)

-332.4M

Earnings Y/Y

37.2%

Earnings Q/Q

65.18%

Price Action

52 Week Range

1.386.74
(Low)(High)

Last 7 days

-7.2%

Last 30 days

-15.2%

Last 90 days

-13.1%

Trailing 12 Months

-70.7%

Financial Health

Current Ratio

3.18

Investor Care

Shares Dilution (1Y)

12.27%

Diluted EPS (TTM)

-1.29

Peers (Alternatives to Inovio Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
12.69% 40.17%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
1.16% -37.31%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.98% 19.60%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.97% 52.06%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.42% 24.09%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
4.50% 46.57%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
15.89% 47.00%
-19.93
12.09
35.70% -47.34%
MID-CAP
3.8B
-
13.27% -45.82%
-5.86
917.1
-74.20% -52.72%
2.9B
334.3M
11.20% -50.29%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.4B
1.2B
-22.47% -63.78%
-7.1
1.01
-34.68% -517.43%
631.1M
23.8M
-13.64% -94.46%
-10.41
22.9
-17.54% -36.25%
551.2M
2.2M
-15.17% -70.66%
-1.55
343.43
-72.60% -50.35%
417.6M
152.4M
3.22% -21.48%
-37.92
2.75
5.37% -174.76%
124.1M
526.0K
-16.57% -64.48%
-5.78
236.85
-16.85% -4.48%
45.8M
9.9M
16.03% -24.71%
-6.29
4.24
-2.79% -85.01%

Financials for Inovio Pharmaceuticals

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue37.4%2,2041,6051,6751,7758,044
Operating Expenses-4.5%328,112343,446321,999302,993231,565
Earnings Before Taxes6.3%-330,137.29-352,522.44-326,165.09-303,224.32-218,691.94
Net Income6.3%-332,354.93-354,740.07-328,382.72-303,700.00-221,047.38
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-14.7%392459446496536
  Current Assets-15.9%350416400448487
    Cash Equivalents-46.5%2241597168
Liabilities-22.5%125162909682
  Current Liabilities-27.6%95131596651
Shareholder's Equity-10.4%267298355400454
  Retained Earnings-2.7%-1,433.38-1,395.60-1,287.10-1,209.86-1,102.91
Shares Outstanding7.5%235219217210-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-10.7%-217.77-196.79-224.72-215.71-229.03
  Share Based Compensation-8.8%2527242625
Cashflow From Investing-18.8%4960121-175.34-172.57
Cashflow From Financing3.6%12311979211291

Risks

What is the probability of a big loss on INO?

100%


Probability that Inovio Pharmaceuticals stock will be more than 20% underwater in next one year

97.3%


Probability that Inovio Pharmaceuticals stock will be more than 30% underwater in next one year.

86.9%


Probability that Inovio Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Inovio Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on INO

-13.6%


10-Year Cumulative Returns

-17.2%


7-Year Cumulative Returns

-16.4%


5-Year Cumulative Returns

-9.1%


3-Year Cumulative Returns

What are the long-term rolling returns for INO?

FIve years rolling returns for Inovio Pharmaceuticals.

Which funds bought or sold INO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
National Asset Management, Inc.
SOLD OFF
-100
-55,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
ADDED
8.76
39,000
508,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-1,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
-
-%
2022-11-15
Blume Capital Management, Inc.
UNCHANGED
-
-
2,000
-%
2022-11-15
Balyasny Asset Management LLC
ADDED
15.66
15,000
113,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-19.16
-10,804,000
44,895,000
-%
2022-11-15
Covington Capital Management
UNCHANGED
-
-
2,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying INO calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own INO

Inovio Pharmaceuticals News

FierceBiotech

Summit bets $5B that Akeso's bispecific antibody will ascend clinical peaks in cancer.29 hours ago

The Motley Fool

INO Fair Value

Recent SEC filings of Inovio Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
10-Q
Quarterly Report
Oct 14, 2022
UPLOAD
UPLOAD
Sep 29, 2022
CORRESP
CORRESP
Sep 15, 2022
UPLOAD
UPLOAD

Latest Insider Trading transactions for INO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-11
Weiner David B.
ACQUIRED
25,650
2.16
11,875
-
2022-08-11
Weiner David B.
SOLD
-31,587.5
2.66
-11,875
-
2022-07-20
BENITO SIMON X
ACQUIRED
4,400
2.2
2,000
-
2022-07-20
BENITO SIMON X
SOLD
-4,500
2.25
-2,000
-
2022-05-16
Weiner David B.
SOLD
-17,550
1.95
-9,000
-
2022-05-16
Zoth Lota S.
SOLD
-7,128
1.98
-3,600
-
2022-05-13
Miller Ann Calby
ACQUIRED
-
-
18,000
-
2022-05-13
DANSEY ROGER D
ACQUIRED
-
-
12,000
-
2022-05-13
YARNO WENDY L
ACQUIRED
-
-
18,000
-
2022-05-13
Zoth Lota S.
ACQUIRED
-
-
18,000
-

1–10 of 50

Jacqueline E. Shea
320
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenue from collaborative arrangements and other contracts$ 9,154,133$ 291,698$ 10,137,602$ 935,643
Operating expenses:    
Research and development33,087,13047,088,669145,530,626156,941,505
General and administrative11,824,04713,156,18376,234,34139,703,718
Total operating expenses44,911,17760,244,852221,764,967196,645,223
Loss from operations(35,757,044)(59,953,154)(211,627,365)(195,709,580)
Other income (expense):    
Interest income1,365,759766,2712,893,2402,463,618
Interest expense(313,488)(476,374)(940,464)(1,456,134)
Loss on investment in affiliated entities(305,061)(21,999)(1,776,804)(573,656)
Net unrealized loss on available-for-sale equity securities(1,833,284)(455,299)(10,641,026)(1,166,764)
Other (expense) income, net(940,778)(28,486)(1,097,294)165,773
Net loss before share in net loss of Geneos(37,783,896)(60,169,041)(223,189,713)(196,276,743)
Share in net loss of Geneos00(2,165,213)(434,387)
Net loss$ (37,783,896)$ (60,169,041)$ (225,354,926)$ (196,711,130)
Net loss per share    
Basic (in dollars per share)$ (0.15)$ (0.29)$ (0.96)$ (0.95)
Diluted (in dollars per share)$ (0.15)$ (0.29)$ (0.96)$ (0.95)
Weighted average number of common shares outstanding    
Basic (in shares)249,351,023210,304,836234,634,724207,455,684
Diluted (in shares)249,351,023210,304,836234,634,724207,455,684

INO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 21,988,239$ 71,143,778
Short-term investments259,894,898330,170,940
Accounts receivable2,442,8665,466,850
Accounts receivable from affiliated entities7,637,8202,565,194
Prepaid expenses and other current assets57,970,97938,836,991
Prepaid expenses and other current assets from affiliated entities273,211261,192
Total current assets350,208,013448,444,945
Fixed assets, net15,588,10317,453,206
Investment in affiliated entity2,129,9923,906,796
Intangible assets, net2,249,4442,626,355
Goodwill10,513,37110,513,371
Operating lease right-of-use assets10,577,07711,571,026
Other assets701,9861,425,794
Total assets391,967,986495,941,493
Current liabilities:  
Accounts payable and accrued expenses74,147,79247,644,530
Accounts payable and accrued expenses due to affiliated entities1,633,788548,032
Accrued clinical trial expenses13,485,84610,326,266
Deferred revenue021,628
Operating lease liability2,820,8622,603,956
Grant funding liability2,709,9534,559,721
Grant funding liability from affiliated entity116,50037,500
Total current liabilities94,914,74165,741,633
Deferred revenue, net of current portion064,361
Convertible senior notes16,301,35214,959,647
Operating lease liability, net of current portion13,312,38315,459,559
Deferred tax liabilities32,04632,046
Other liabilities710,34814,826
Total liabilities125,270,87096,272,072
Stockholders’ equity:  
Preferred stock00
Common stock249,484217,382
Additional paid-in capital1,700,717,4891,609,589,797
Accumulated deficit(1,433,384,645)(1,209,855,522)
Accumulated other comprehensive loss(885,212)(282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity266,697,116399,669,421
Total liabilities and stockholders’ equity$ 391,967,986$ 495,941,493